Walter G Deberdt

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
    Walter Deberdt
    Eli Lilly Benelux, Eli Lilly and Company, Brussels, Belgium
    Ther Clin Risk Manag 4:713-20. 2008
  2. pmc Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    University Leuven, Kortenberg, Belgium
    BMC Psychiatry 12:130. 2012
  3. pmc Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
    BMC Psychiatry 9:44. 2009
  4. ncbi request reprint Amantadine for weight gain associated with olanzapine treatment
    Walter Deberdt
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 15:13-21. 2005
  5. ncbi request reprint Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
    Walter G Deberdt
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 13:722-30. 2005
  6. ncbi request reprint Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis
    Walter G Deberdt
    Eli Lilly and Company, Brussels, Belgium
    Int J Geriatr Psychiatry 23:364-9. 2008
  7. ncbi request reprint Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
  8. ncbi request reprint Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
  9. doi request reprint Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 170:161-7. 2009

Detail Information

Publications9

  1. pmc Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
    Walter Deberdt
    Eli Lilly Benelux, Eli Lilly and Company, Brussels, Belgium
    Ther Clin Risk Manag 4:713-20. 2008
    ....
  2. pmc Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    University Leuven, Kortenberg, Belgium
    BMC Psychiatry 12:130. 2012
    ....
  3. pmc Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
    BMC Psychiatry 9:44. 2009
    ..This post-hoc analysis evaluates the relationships among cognition, psychopathology, and psychosocial functioning in patients with schizophrenia at baseline and following sustained treatment with antipsychotic drugs...
  4. ncbi request reprint Amantadine for weight gain associated with olanzapine treatment
    Walter Deberdt
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 15:13-21. 2005
    ..Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy...
  5. ncbi request reprint Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
    Walter G Deberdt
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 13:722-30. 2005
    ..The authors compared efficacy of olanzapine versus placebo and risperidone as measured by the Neuropsychiatric Inventory and Clinical Global Impression-Severity of Psychosis scale in patients with dementia-related psychosis...
  6. ncbi request reprint Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis
    Walter G Deberdt
    Eli Lilly and Company, Brussels, Belgium
    Int J Geriatr Psychiatry 23:364-9. 2008
    ..This study was conducted to determine the effect of olanzapine treatment on cognition in elderly patients with behavioral and psychiatric symptoms (BPSD) associated with dementia...
  7. ncbi request reprint Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
    ..The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications...
  8. ncbi request reprint Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
    ..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...
  9. doi request reprint Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach
    Ilya A Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 170:161-7. 2009
    ..Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice...